Company / Operating Cash Flow
Haemonetics Operating Cash Flow History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
$181.7M
FY2024
5-year range
$172.3M / $273.1M
FY2020-FY2024
Trend
-0.0%
vs FY2023
Sector context
#88 of 158
Health Care
What the data says
At $182M, Haemonetics's operating cash flow ranks #88 of 158 in the Health Care sector. Operating Cash Flow has fluctuated over the past 9 years, ranging from $109M in FY2020 to $273M in FY2022.
Based on SEC 10-K filings.
$182M in FY2024 with a 5-year CAGR of +2.8%.
Declined from $273M to $182M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- +1.8%
- 5-Year CAGR
- +2.8%
- 10-Year CAGR
- -
Sector benchmark
#88 of 158 in Health CareTop 56% of 158This company $181.7M Sector average $1.0B
▼
-82.4% below sector average
Key checks
Key Insights
- 5-year CAGR of +2.8%, indicating consistent growth.
- In FY2024, operating cash flow decreased 0.0% year-over-year.
- Ranks #88 out of 158 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score 0.44 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $181.7M | -0.0% |
| FY2023 | $181.8M | -33.4% |
| FY2022 | $273.1M | +58.5% |
| FY2021 | $172.3M | +58.3% |
| FY2020 | $108.8M | -31.2% |
| FY2019 | $158.2M | -0.7% |
| FY2018 | $159.3M | -27.7% |
| FY2017 | $220.3M | +37.9% |
| FY2016 | $159.7M | +31.1% |
As of FY2024 · SEC 10-K · Updated Mar 28, 2026